FLT3 ligand in acute myeloid leukemia: a simple test with deep implications

Péterlin, Pierre; Chevallier, Patrice; Knapper, Steven; Collin, Matthew

doi:10.1080/10428194.2020.1834091

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…The FMS-related tyrosine kinase 3 ligand (Flt-3L) is a transmembrane protein that can be secreted as a soluble protein [ 7 , 8 ]. It is an important regulator of hematopoiesis and has a pivotal role in dendric cell activation [ 7 , 8 ]. Flt-3L acts through the FMS-related tyrosine kinase 3(Flt-3) present on the multipotent progenitors and common lymphoid progenitors as their growth factor but not on mature cells, apart from DC [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy

Kuncman

Orzechowska

Stawiski

et al. 2022

Cancers

View full text Add to dashboard Cite

The optimal sequence of chemoradiotherapy with immunotherapy is still not established. The patient’s immune status may play a role in determining this order. We aim to determine the kinetics of a multi-potential haemopoietic factor FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy. Our pilot, a single arm prospective study, enrolled patients with rectal cancer who qualified for neoadjuvant chemoradiotherapy. Blood samples for Flt-3L were collected before and every second week of chemoradiotherapy for a complete blood count every week. The kinetics of Flt-3L were assessed using Friedman’s ANOVA. A multiple factor analysis (MFA) was performed to find relevant factors affecting levels of serum Flt-3L during chemoradiotherapy. FactoMineR and factoextra R packages were used for analysis. In the 33 patients enrolled, the level of Flt-3L increased from the second week and remained elevated until the end of treatment (p < 0.01). All patients experienced Grade ≥2 lymphopenia with a nadir detected mostly in the 5/6th week. MFA revealed the spatial partitioning of patients among the first and second dimensions (explained by 38.49% and 23.14% variance). The distribution along these dimensions represents the magnitude of early changes of Flt-3L. Patients with the lowest values of Flt-3L change showed the highest lymphocyte nadirs and lowest dose/volume parameters of active bone marrow. Our hypothesis-generating study supports the concept of early initiation of immuno-therapy when the concentration of Flt-3L is high and no lymphopenia has yet occurred.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy

Kuncman

Orzechowska

Stawiski

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…We identified the four novel inflammatory factors as possibly involved in macular edema: FMS-related tyrosine kinase 3 ligand (Flt-3L), fractalkine, CXC chemokine ligand 16 (CXCL-16), and endocan-1. Flt-3L, a transmembrane protein, can also take the form of a soluble protein [12,13]. As a cytokine, it is involved in the differentiation of hematopoietic stem cells and their mobilization.…”

Section: Introductionmentioning

confidence: 99%

“…As a cytokine, it is involved in the differentiation of hematopoietic stem cells and their mobilization. Flt-3L also regulates hematopoiesis and activates dendrites [12,13]. In addition, it causes lymphocyte proliferation [14].…”

Section: Introductionmentioning

confidence: 99%

Role of Novel Inflammatory Factors in Central Retinal Vein Occlusion with Macular Edema

Yasuda,

Noma,

Mimura

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: To investigate associations among the aqueous humor levels of novel inflammatory factors, including FMS-related tyrosine kinase 3 ligand (Flt-3L), fractalkine, CXC chemokine ligand 16 (CXCL-16), and endocan-1; the severity of macular edema in central retinal vein occlusion (CRVO); and the prognosis of CRVO with macular edema after antivascular endothelial growth factor (VEGF) therapy. Materials and Methods: Aqueous humor was obtained during anti-VEGF treatment with intravitreal ranibizumab injection (IRI) in patients with CRVO and macular edema (n = 19) and during cataract surgery in patients with cataracts (controls, n = 20), and the levels of VEGF and novel inflammatory factors were measured. Macular edema was evaluated by central macular thickness (CMT) and neurosensory retinal thickness (TNeuro), and improvement was evaluated by calculating the percentage change in CMT and TNeuro from before to 1 month after IRI. Results: The levels of VEGF and the novel inflammatory factors were significantly higher in the CRVO group, and the levels of Flt-3L, CXCL-16, and endocan-1 were significantly correlated with each other and with the aqueous flare value. Baseline levels of Flt-3L, CXCL-16, and endocan-1 had a significantly negative correlation with the change in CMT, and the baseline level of CXCL-16 was significantly negatively correlated with the change in TNeuro. Conclusions: Relations among novel inflammatory factors should be further investigated. These findings may help improve understanding of macular edema in CRVO patients and aid the development of new treatments targeting novel inflammatory factors.

show abstract